![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Tentatively Approves Eagle Pharma’s Alimta Copycat
FDA Tentatively Approves Eagle Pharma’s Alimta Copycat
![Purple_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Purple_Approved_Stamp.gif?t=1576639773&width=430)
The FDA granted tentative approval to Eagle Pharmaceuticals’ version of Eli Lilly’s cancer drug Alimta.
Final approval hinges on the result of a patent battle with Lilly. If Eagle secures that approval, the firm expects to capture between a quarter and a third of the market.
Lilly filed the lawsuit last month, arguing the company infringed on its patents for Alimta, which made Lilly $2.28 billion last year. If the patents are ruled valid, no other company can market a cheaper alternative in the U.S. through May 2022.
Upcoming Events
-
21Oct